"The first immediate action calls on the FDA to 'evaluate the inclusion of list prices in direct-to-consumer advertising.' ... The second immediate action calls on [CMS] to update Medicare's drug-pricing dashboard 'to make price increases and generic competition more transparent.' ... The use of confidential rebates has become a central feature of our drug reimbursement system, and restricting or reducing their use would significantly change the ways in which drugs are distributed and reimbursed."  MORE >>